4D Molecular Therapeutics Will Host Investor Day October 21
The biotech firm will detail progress on its late-stage retinal and respiratory gene therapy programs.
Updated on Oct. 5, 2026 in Biotech
4D Molecular Therapeutics will host an investor day in New York City on October 21, 2026, to discuss its current clinical pipeline. The event will focus on its lead candidate, 4D-150, which is currently in Phase 3 development for wet age-related macular degeneration and diabetic macular edema.
Why it matters
The company is providing an update on its therapeutic development strategy as it advances late-stage gene therapy candidates. None of the company's product candidates have currently received regulatory approval.
The company is advancing 4D-150, a gene therapy candidate designed for delivery via a single intravitreal injection, which is currently undergoing Phase 3 clinical evaluation.
The players
4D Molecular Therapeutics
A biotechnology company headquartered in Emeryville, California, focused on developing genetic medicines for serious diseases.
The details
4D-150 is a gene therapy candidate aimed at treating retinal diseases through a single intravitreal injection—an injection into the clear gel-like substance in the eye. The company is also developing 4D-710, a candidate currently in research for cystic fibrosis. These therapies utilize modified viral vectors to deliver genetic material to target cells, a mechanism that remains in the experimental stage.
Timeline
October 21, 2026
10:30am ET
The Tech Race
The investor event underscores the competitive pressure to establish efficacy and safety profiles for AAV-based gene therapies. This effort follows a broader trend of companies seeking to move sophisticated genetic medicines from research into late-stage clinical adoption.
The event provides transparency for investors and researchers regarding the clinical status of upcoming therapies that currently lack regulatory approval. Interested parties may access the session via a live webcast or review the archives after the presentation concludes.
The takeaway
The event will clarify the company's progress in navigating late-stage clinical hurdles for its lead retinal therapy. Interested observers should monitor the Q&A session for new data on the 4D-150 Phase 3 enrollment status.
What happens next
An archived webcast of the event will be available for one year starting October 21, 2026.
Further reading
For broader context on current developments in gene therapy and clinical pipeline progress, see the latest updates on Biotech.
More information
To join the session or access materials, visit the investor day webcast registration.
